Jazz Pharmaceuticals And The University Of Texas MD Anderson Cancer Center Announced A Five-year Research Agreement For Zanidatamab, Jazz's Investigational HER2-Targeted Bispecific Antibody
Portfolio Pulse from Benzinga Newsdesk
Jazz Pharmaceuticals and The University of Texas MD Anderson Cancer Center have announced a five-year research agreement for Zanidatamab, Jazz's investigational HER2-targeted bispecific antibody. The collaboration will fund multiple studies over its five-year term, with research expected to begin in late 2023 or early 2024.
November 07, 2023 | 12:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jazz Pharmaceuticals has entered into a five-year research agreement with MD Anderson Cancer Center for Zanidatamab, potentially leading to advancements in cancer treatment and boosting Jazz's product portfolio.
The partnership with MD Anderson Cancer Center for the research on Zanidatamab, a potential cancer treatment, could lead to significant advancements in the field and boost Jazz's product portfolio. This could potentially increase investor interest and positively impact Jazz's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100